J. Chem Soc. Nigeria, Vol. 43, No. 4, pp 767 -776 [2018]

POTENT I*N VITRO* BIOLOGICAL ACTIVITY OF SOME DERIVATIVES OF SYNTHESIZED C-9154 ANTIBIOTIC

I.A. Bello[*1,2], E.O. Bello[3], Y. Isah[4]

1. School of Chemistry, University of Kwazulu-Natal, Durban - South Africa
2. Department of Chemistry, Ahmadu Bello University, Zaria – Nigeria
3. Department of Biochemistry, Ahmadu Bello University, Zaria – Nigeria
4. Department of Chemistry, Federal University Lokoja – Nigeria

* corresponding author: lobell_ng@yahoo.com, +2348053465344

Received 01 September 2018; accepted 30 September 2018, published online 07 October 2018

ABSTRACT

This research was undertaken to design several new antibiotics, by structurally modifying the C-9154 antibiotic simultaneously improving activity and lowering toxicity as part of our continued attempts at designing new antibiotics. An analogue to the C-9154 antibiotic and six derivatives of this analogue were synthesized. The approach was to significantly reduce the polarity of the synthesized analogue in the derivatives to achieve increased permeability across cell membranes by conversion of the highly polar carboxylic group to an ester functional group. The compounds were synthesized by condensation of 3-aminophenol with maleic anhydride and then conversion of the terminal carboxylic acid functional group to ester functional group using a thionyl chloride-mediated esterification process. The *in vitro* biological activity showed that the derivatives were more active than the analogue and significantly better than the standard drugs used for comparison. The compounds were fully characterized using Infrared, GC-MS and 1D and 2D NMR experiments.

KEYWORDS; Antibiotics, Bioactivity, C-9154, Maleic anhydride, NMR, Synthesis

INTRODUCTION

After the 'fall of man', fighting disease has become a normal part of his existence. This he does by the use of compounds derived from nature. One such class of compounds is called antibiotics. Vuillemin, a French bacteriologist, suggested using the word 'antiobiosis', meaning 'against life,' to describe the group of drugs that had detrimental effect against microorganisms [1]. Selman Waksman, the discoverer of streptomycin, later changed this term to antibiotic in 1942 [2]. The term 'antibiotic' is used to describe any substance produced by a microorganism that is antagonistic to the growth of other microorganisms in high dilution (low concentration) [3]. With current advances in medicinal chemistry, antibiotics are now mostly semisynthetic modifications of various natural compounds [4]. Some antibiotic compounds are still being isolated from living organisms like the aminoglycosides, whereas other antibiotics like the sulfonamides, the quinolones, and the oxazolidinones are produced solely by chemical synthesis [4]. This implies that synthesis of antibiotic compounds plays an important and vital role in the fight against disease-causing organisms. In light of emerging resistance to current antibiotic drugs, it has become imperative to synthesize new antibiotics to combat these resistances. The problem of resistance to antibiotics on the part of the microorganism, the adverse side effects associated with antibiotics in current use and the difficulty in obtaining these antibiotics in large (commercial) quantities from their natural sources implies that newer antibiotics have to be constantly sought to address these problems to give man the needed advantage in the ongoing battle between microbes and men. Synthesis of previously characterized antibiotics with structural modifications to imbue desirable qualities or remove undesirable ones provides a way to assist man in this great battle.

During studies on screening for antibiotics that showed activity against bacteria resistant to various known antibiotics, a new antibiotic with a broad antibacterial spectrum was isolated from the whole agar culture of *Streptomyces* strain NR-7GGI. This Streptomyces specie was called *Streptomyces kurssanovii* and the isolated antibiotic referred to as fumaramidmycin [5]. Another researcher working independently and slightly earlier than the previous researcher also found that a new species of *Streptomyces*, *Streptomyces ishigakiensis* produced a novel antibiotic which was named C-9154 [6]. The two new antibiotics were found from structural studies to be one and the same compound [6, 7]. This new antibiotic was found to inhibit the growth of various microorganism at concentrations between 10 - >100 µg/mL [6]. It was also shown to be active against certain strains that were resistant to ampicillin, cephalosporin, chloramphenicol, gentamicin, kanamycin, macrolides, neomycin, sulfonamides, streptomycin and tetracyclines at concentrations between 3.12 - >200 µg/mL [5]. Its intraperitoneal LD_{50} value in mice was found to be between 75-100 mg/kg while its oral LD_{50} was found to be 1.25 - 2.5 g/kg [5]. The structure of C-9154 (Figure 1) was determined using elemental analysis procedures, IR and UV measurements and NMR and GC-MS experiments [7, 8].



Figure 1: C-9154 Antibiotic

Analysis of the structure of C-9154 antibiotic showed that it was made up of two fragments, namely, phenyl acetic acid and fumaramide [6, 7]. Analogues of the C-9154 antibiotic have been previously synthesized [7 - 10]. We have

previously reported the syntheses of some of these analogues and their biological activity profile [11, 12].

We now report the syntheses of one analogue and six derivatives of the C-9154 antibiotic - five of which are being reported for the first time - and their *in vitro* biological activity which has never before been reported.

EXPERIMENTAL

Infrared spectra were determined using a PerkinElmer Spectrum 100 series Universal ATR. 1D and 2D NMR experiments were carried out using a Bruker av400MHz NMR. The GC/MS spectra were taken using an Agilent Technologies 6890 series GC coupled with an Agilent 5973 Mass Selective detector.

All chemicals and reagents unless otherwise stated were obtained from Merck Chemicals, Germany while all media were obtained from Oxoid, England.

Synthesis of C-9154 Analogue

The analogue was synthesized using the following procedure. N-[(3-hydroxyphenyl) amino] fumaramic acid was prepared according to reaction scheme 1 (Figure 2). 3-aminophenol (1.0g, 9.2mmol) in toluene (5mL) was transferred to a round bottom flask containing maleic anhydride (1.1g, 11.2mmol) in toluene (5mL). The mixture was refluxed at 95°C with stirring for 2hrs. The reaction was allowed to cool to room temperature and filtered using a Buchner funnel. The residue was washed using ethyl acetate and dried to afford a yellow solid labeled IA/09/1 (1.7g, 89.0%). TLC was used to determine that the reaction had gone to completion. IR, NMR and GC-MS were used to identify the compound as the desired N-[3-hydroxyphenyl) amino] fumaramic acid. Its melting point was determined to be 190-191°C.



Figure 2: Reaction Scheme 1

Synthesis of Derivatives of C-9154 Analogue

This analogue was then converted to its ester derivatives using methanol, ethanol, n-propanol, isopropanol, n-butanol, and 2-butanol respectively and a thionyl chloride ($SOCl_2$) mediated esterification procedure according to reaction scheme 2 (Figure 3). Six portions of IA/09/1 (0.5g, 2.4mmol) were individually transferred to six round bottomed flasks in ice baths. Thionyl chloride (2mL) was added in drops with constant stirring. The excess thionyl chloride was removed using a rotary evaporator. Methanol (10mL), ethanol (10mL), n-propanol (10mL), isopropanol (10mL), n-butanol (10mL), and 2-butanol (10mL) were respectively added to each flask and the mixtures refluxed. At the end of the reactions as determined by TLC, saturated sodium carbonate (Na_2CO_3) solution was added to each flask until the solutions just turned alkaline as indicated by litmus paper. Water (20mL) was added to each flask and the mixtures were individually transferred to different separatory funnels. The mixtures in the different separatory funnels were extracted using dichloromethane (2 x 25mL). The combined dichloromethane fractions were individually dried using anhydrous sodium sulphate (Na_2SO_4) and concentrated to give dark brown oils. These were chromatographed on separate silica gel columns and eluted using ethyl acetate:hexane (3:7), to give the desired esters which crystallized on standing. All the esters were obtained as crystalline solids (Table 1). IR, NMR and GC-MS were used to identify the compounds as the desired esters.



Figure 3: Reaction Scheme 2

Table 1: Synthesized C-9154 analogue and its derivatives

Sample Code	Type	Yield (mg)	Melting point (°C)	Physical State
IA/09/1	C-9154 Analogue	89%	190-191	Yellow amorphous Solid
IA/37/1/B	Methyl ester	175, (0.79mmol)	119	Light brown crystalline solid
IA/38/1/B	Ethyl ester	75, (0.32mmol)	115	Dark brown crystalline solid
IA/39/1/B	n-propyl ester	40, (0.16mmol)	176	Dark brown crystalline solid
IA/40/1/B	Isopropyl ester	80, (0.32mmol)	154	Light brown crystalline solid
IA/41/1/B	n-butyl ester	105, (0.40mmol)	110	Brown crystalline solid
IA/42/1/B	2-butyl ester	60, (0.23mmol)	102	Yellowish brown crystalline solid

Biological Screening

These compounds were then subjected to biological screening *in vitro* to ascertain their activity and the concentration at which this activity was exhibited.

This was carried out using Zones of inhibition measurements, Minimum Inhibitory Concentration measurements (MIC) and Minimum Bactericidal/Fungicidal Concentration measurements (MBC/MFC). Fourteen (14) microorganisms were selected for the screening to include both gram-positive and gram-negative bacteria and some fungi. These microorganisms are: Methicillin-Resistant *Staphylococcus aureus, Staphylococcus aureus, Streptococcus pyogenes, Bacillus subtilis,* and *Corynebacterium ulcerans* for gram positive bacteria, *Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa, Salmonella typhii, Shigella dysenteriae,* and *Klebsiella pneumonia* for gram negative, and *Candida albicans, Aspergillus nigre* and *Trichophyton rubrum* for fungi.

Zones of Inhibition

The antimicrobial activity (Table 2) of the synthesized analogues and derivatives was determined using some pathogenic microorganisms obtained from the Department of Medical Microbiology, Ahmadu Bello University Teaching Hospital, Zaria, Nigeria. All isolates were checked for purity and maintained in slants of blood agar.

The analogues (0.1mg) and the derivatives (0.05mg) were each weighed and dissolved in DMSO (10mL) to obtain a concentration of 10µg/mL and 5µg/mL respectively. This was the initial concentration used to check the antimicrobial activities of the compounds. Mueller Hinton and Sabouraud agar were used as growth media for the bacteria and fungi respectively. The media were prepared according to the manufacturer's instructions, sterilized at 121°C for 15 minutes and were poured into sterile Petri dishes. The plates were allowed to cool and solidify. Diffusion method was the method used for screening the compounds. The sterilized

media were seeded with a standard inoculum (0.1mL) of the test microorganisms. This was spread evenly over the surface of the plate by using a sterile swab. The plates were dried at 37°C for 30 minutes. Using a standard cork-borer of 6mm in diameter, a well was cut at the centre of each seeded plate. 0.1mL of the compounds was then introduced into the well. The plates were then incubated at 37°C for 24hrs for the bacteria and 30°C for 48hrs for the fungi, after which the plates were observed for zones of inhibition of growth. The zones were measured using a pair of dividers and a ruler and the result recorded in millimeters.

The activity of the compounds was compared against two standard drugs; Sparfloxacin (antibacterial) and Fluconazole (antifungal).

Minimum Inhibitory Concentration

The minimum inhibitory concentrations (Table 3) of the compounds were carried out using broth dilution method. Mueller Hinton and Sabouraud dextrose broth, were prepared and 10mL was dispensed into test-tubes and the broths were sterilized at 121°C for 15 minutes and allowed to cool. McFarland's turbidity scale number 0.5 was prepared to give turbid solution.

Normal saline was prepared and the test microorganisms were inoculated and incubated at 37°C for 6hrs. Dilution of the test microorganisms were done continuously in the normal saline until the turbidity matched that of the McFarland's scale by visual comparison. At that point the test microbe was at a concentration of about 1.5 x 10^8 CFU/mL.

Table 2. Zones of inhibition (mm) of the analogue and derivatives

	IA/09/1 (10µg/mL)	**IA/37/1/B (5µg/mL)**	**IA/38/1/B (5µg/mL)**	**IA/39/1/B (5µg/mL)**	**IA/40/1/B (5µg/mL)**	**IA/41/1/B (5µg/mL)**	**IA/42/1/B (5µg/mL)**	**DMSO**	**Sparfloxacin (20µg/mL)**	**fluconazole (50µg/mL)**
MRSA	21	30	31	27	34	37	31	0	22	0
S. aureus	25	31	30	29	32	35	27	0	27	0
S. pyogenes	22	27	26	0	0	37	27	0	24	0
B. subtilis	30	35	32	30	37	37	30	0	30	0
C. ulcerans	0	29	27	24	0	29	0	0	0	0
E. coli	22	30	32	27	29	31	27	0	27	0
P. mirabilis	22	26	29	0	27	30	26	0	22	0
P. aeruginosa	0	0	0	0	0	0	0	0	20	0
S. typhii	20	24	25	24	26	29	27	0	21	0
S. dysenteriae	27	24	23	20	24	23	25	0	27	0
K. pneumoniae	27	26	26	22	20	21	24	0	25	0
C. albicans	20	22	21	19	20	21	20	0	0	24
A. nigre	20	0	0	0	0	0	0	0	0	0
T. rubrum	0	0	0	0	0	0	0	0	0	20

Two-fold serial dilutions of the compounds in the broth were made to obtain the different concentrations of the compounds in the broth. Having obtained the different concentrations, 0.1mL of the standard inoculum of the test microorganisms in the normal saline were then inoculated into the different concentrations, and then incubated at 37°C for 24hrs for the bacteria and 30°C for 48hrs for the fungi, after which each test tube was observed for turbidity (growth). The MIC was the test tube with the lowest concentration of the compounds which showed no turbidity.

Minimum Bactericidal/Fungicidal Concentration

MBC (Table 3) was carried out to check whether the test microorganisms were killed or only their growths were inhibited. Mueller Hinton and Sabouraud dextrose agar were prepared, sterilized and poured into sterile Petri dishes. These were allowed to cool and solidify. The content of the MIC in the serial dilution were then sub-cultured onto the prepared media. These were then incubated at 37°C for 24hrs for the bacteria and 30°C for 48hrs for the fungi after which each plate was observed for colony growth. The MBC/MFC was the plate with lowest concentration of the compounds without colony growth.

RESULTS

Seven compounds were synthesized and fully characterized using 1D and 2D NMR experiments, infrared spectrophotometry and gas chromatography-mass spectrometry.

The analogue was synthesized by reaction between the required N-phenyl amine (3-amino phenol) and maleic anhydride to get the desired fumaramic acid. This analogue was then converted to its methyl, ethyl, n-propyl, isopropyl, n-butyl, and 2-butyl esters using a thionyl chloride - mediated esterification procedure. These compounds were then subjected to biological screening *in vitro.* The results and associated data are presented below.

IA/09/1 (N-[(3-hydroxyphenyl) amino] fumaramic acid). This was obtained as a yellow solid with a melting point of 190-191°C.

^{13}C-NMR (100MHz, DMSO-d_6). 166.8 (C10), 163.1 (C7), 157.6 (C3), 139.4 (C1), 131.6 (C9), 130.5 (C8), 129.4 (C5), 111.0 (C4), 110.3 (C6), 106.7 (C2).

^{1}H-NMR (400MHz, DMSO-d_6) δ 6.28 (1H, d, J=12.05 Hz, H-9), 6.45 (1H, d, J=12.09 Hz, H-8), 6.49 (1H, dd, J=1.78, 7.98 Hz, H-6), 6.97 (1H, d, J=8.16 Hz, H-4), 7.09 (1H, t, J=8.04 Hz, H-5), 7.21 (1H, s, H-2), 9.42 (1H, s, 3-OH), 10.27 (1H, s, 1-NH), 13.14 (1H, s, 10-OH).

EI-MS: m/z 206 {[M - H]$^+$, 100%}.

IR_{vmax} (neat) cm^{-1} : 3306.12 (N-H), 3201.36 (O-H), 2728.05 (C-H), 1700.72, 1605.21 (C=O).

IA/37/1/B (Methyl N-[(3-hydroxyphenyl) amino] fumaramate). This was obtained as a light brown shiny crystalline solid with a melting point of 119°C.

^{13}C-NMR (100MHz, $CDCl_3$). 169.6 (C7), 156.9 (C10), 156.3 (C3), 134.2 (C9), 132.1(C1), 130.1 (C8), 129.9 (C5), 118.1 (C4), 115.3 (C6), 113.3 (C2), 53.0 (C11).

^{1}H-NMR (400MHz, $CDCl_3$) δ 3.86 (3H, s, H-11), 6.25 (1H, d, J=13.4 Hz, H-8), 6.45 (1H, d, J=13.32, H-9), 6.66 (1H, dd, J=2.10, 8.10 Hz, H-4), 6.94 (1H, dd, J=1.04, 7.92 Hz, H-6), 7.19 (1H, t, J=8.08 Hz, H-5), 7.32 (1H, t, J=8.06 Hz, H-2), 7.78 (1H, s, 3-OH), 11.10 (1H, s, 1-NH).

EI-MS: m/z 220 {[M - H]$^+$, 100%}.

IR_{vmax} (neat) cm^{-1} : 3410.55 (N-H), 3095.64 (O-H), 2983.22 (C-H), 1712.42, 1663.82 (C=O).

Table 3: Minimum Inhibitory Concentration (above) and Minimum Bactericidal/Fungicidal Concentration (below) of the analogue and derivatives (µg/mL)[a]

	IA/09/1	**IA/37/1/B**	**IA/38/1/B**	**IA/39/1/B**	**IA/40/1/B**	**IA/41/1/B**	**IA/42/1/B**	**DMSO**	**Sparfloxacin**	**Fluconazole**
MRSA	2.5 10	0.625 2.5	0.625 2.5	1.25 5	0.625 2.5	0.625 1.25	0.625 2.5	ND	10	ND
S. aureus	2.5 5	0.625 2.5	0.625 2.5	1.25 2.5	0.625 2.5	0.625 2.5	1.25 5	ND	10	ND
S. pyogenes	2.5 10	1.25 5	1.25 5	ND ND	ND ND	0.625 1.25	1.25 5	ND	10	ND
B. subtilis	1.25 5	0.625 1.25	0.625 2.5	0.625 5	0.625 1.25	0.625 2.5	0.625 2.5	ND	5	ND
C. ulcerans	ND ND	1.25 2.5	1.25 5	1.25 5	ND ND	1.25 5	ND ND	ND	ND	ND
E. coli	2.5 10	0.625 2.5	0.625 2.5	1.25 5	1.25 2.5	0.625 2.5	1.25 5	ND	10	ND
P. mirabilis	2.5 10	1.25 5	1.25 2.5	ND ND	1.25 5	0.625 2.5	1.25 5	ND	10	ND
P. aeruginosa	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND	10	ND
S. typhii	2.5 10	1.25 5	1.25 5	1.25 5	1.25 5	1.25 2.5	1.25 5	ND	10	ND
S. dysenteriae	2.5 5	1.25 5	1.25 5	1.25 5	1.25 5	1.25 5	1.25 5	ND	5	ND
K. pneumoniae	2.5 5	1.25 5	1.25 5	1.25 5	1.25 5	1.25 5	1.25 5	ND	5	ND
C. albicans	2.5 10	1.25 5	1.25 5	2.5 5	1.25 5	1.25 5	1.25 5	ND	ND	25
A. nigre	2.5 10	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND	ND	ND
T. rubrum	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND ND	ND	ND	25

[a] Upper values are MIC and lower values are MBC or MFC as the case may be. ND=Not Determined.

IA/38/1/B (Ethyl N-[(3-hydroxyphenyl) amino] fumaramate). This was obtained as a dark brown crystalline solid with a melting point of 115°C.

^{13}C-NMR (100MHz, DMSO-d_6). 166.0 (C7), 162.5 (C10), 157.6 (C3), 139.7 (C1), 132.4 (C9), 129.4 (C5), 128.5 (C8), 110.8 (C4), 110.1 (C6), 106.5 (C2), 60.2 (C11), 13.8 (C12).

^{1}H-NMR (400MHz, DMSO-d_6) δ 1.18 (3H, t, J=7.14 Hz, H-12), 4.12 (2H, q, J=7.10 Hz, H-11), 6.33 (1H, d, J=11.77 Hz, H-8), 6.48 (1H, d, J=9.04, H-4), 6.49 (1H, d, J=11.84 Hz, H-9), 6.96 (1H, d, J=8.16 Hz, H-6), 7.08 (1H, t, J=8.04 Hz, H-5), 7.24 (1H, s, H-2), 9.40 (1H, s, 3-OH)10.13 (1H, s, 1-NH).

EI-MS: m/z 234 {[M - H]$^+$, 100%}.

IR_{vmax} (neat) cm^{-1} : 3264.80 (N-H), 3061.41 (O-H), 2883.61 (C-H), 1716.65, 1662.03 (C=O).

IA/39/1/B (n-propyl N-[(3-hydroxyphenyl) amino] fumaramate). This was obtained as a dark brown crystalline solid with a melting point of 176°C.

^{13}C-NMR (100MHz, DMSO-d_6). 166.0 (C7), 162.5 (C10), 157.6 (C3), 139.7 (C1), 132.6 (C9), 129.3 (C5), 128.4 (C8), 110.7 (C4), 110.1 (C6), 106.4 (C2), 65.7 (C11), 21.3 (C12), 10.2 (C13).

^{1}H-NMR (400MHz, DMSO-d_6) δ 0.86 (3H, t, J=7.42 Hz, H-13), 1.57 (2H, m, H-12), 4.03 (2H, t, J=6.64 Hz, H-11), 6.34 (1H, d, J=11.81 Hz, H-8), 6.46 (1H, d, H-4), 6.50 (1H, d, J=11.84 Hz, H-9), 6.95 (1H, d, J=8.36 Hz, H-6), 7.07 (1H, t, J=8.06 Hz, H-5), 7.22 (1H, s, H-2), 9.39 (1H, s, 3-OH), 10.12 (1H, s, 1-NH).

EI-MS: m/z 247 {[M - 2H]$^+$, 25%}.

IR_{vmax} (neat) cm^{-1} : 3305.69 (N-H), 3184.55 (O-H), 2966.18 (C-H), 1699.97, 1605.00 (C=O).

IA/40/1/B (Isopropyl N-[(3-hydroxyphenyl) amino] fumaramate). This was obtained as a light brown shiny crystalline solid with a melting point of 154°C.

^{13}C-NMR (100MHz, $CDCl_3$). 166.4 (C7), 162.0 (C10), 157.1 (C3), 138.7 (C1), 139.9 (C9), 129.8 (C5), 126.4 (C8), 112.0 (C4), 111.6 (C6), 107.5 (C2), 70.3 (C11), 21.7 (C12 and C13).

^{1}H-NMR (400MHz, $CDCl_3$) δ 1.32 (6H, d, J=6.24 Hz, H-12 and H-13), 5.14 (1H, m, H-11), 6.20 (1H, d, J=13.45 Hz, H-8), 6.41 (1H, d, J=13.33 Hz, H-9), 6.66 (1H, dd, J=2.32, 7.88 Hz, H-4), 6.84 (1H, dd, J=1.16, 7.92 Hz, H-6), 7.19 (1H, t, J=8.06 Hz, H-5), 7.22 (1H, s, H-2), 7.86 (1H, s, 3-OH), 11.29 (1H, s, 1-NH).

EI-MS: m/z 249 {[M]$^+$, 25%}.

IR_{vmax} (neat) cm^{-1} : 3344.01 (N-H), 3167.03 (O-H), 2980.53 (C-H), 1698.86, 1664.13 (C=O).

IA/41/1/B (n-butyl N-[(3-hydroxyphenyl) amino] fumaramate). This was obtained as a brown crystalline solid with a melting point of 110°C.

^{13}C-NMR (100MHz, DMSO-d_6). 165.4 (C7), 162.7 (C10), 157.5 (C3), 139.8 (C1), 132.5 (C9), 129.3 (C5), 128.5 (C8), 110.7 (C4), 110.0 (C6), 106.4 (C2), 72.0 (C11), 28.0 (C12), 19.0 (C13), 9.4 (C14).

^{1}H-NMR (400MHz, DMSO-d_6) δ 0.85 (3H, t, J=7.54 Hz, H-14), 1.17 (2H, m, H-13), 1.54 (2H, q, J=6.99 Hz, H-12), 4.80 (2H, t, J=6.40 Hz, H-11), 6.29 (1H, d, J=11.85 Hz, H-8), 6.45 (1H, d, J=1.80 Hz, H-4), 6.48 (1H, d, J=11.77 Hz, H-9), 6.96 (1H, d, J=8.64 Hz, H-6), 7.07 (1H, t, J=8.04 Hz, H-5), 7.22 (1H, s, H-2), 9.38 (1H, s, 3-OH), 10.09 (1H, s, 1-NH).

EI-MS: m/z 262 {[M - H]$^+$, 100%}.

IR_{vmax} (neat) cm^{-1} : 3275.45 (N-H), 3112.89 (O-H), 2872.53 (C-H), 1718.56, 1662.97 (C=O).

IA/42/1/B (2-butyl N-[(3-hydroxyphenyl) amino] fumaramate). This was obtained as a yellowish brown crystalline solid with a melting point of 102°C.

^{13}C-NMR (100MHz, $CDCl_3$). 166.5 (C7), 162.3 (C10), 157.6 (C3), 138.5 (C1), 139.7 (C9), 129.7 (C5), 126.6 (C8), 112.3 (C4), 111.3 (C6), 107.8 (C2), 74.9 (C11), 28.6 (C12), 19.2 (C14), 9.6 (C13).

^{1}H-NMR (400MHz, $CDCl_3$) δ 0.92 (3H, t, J=7.44 Hz, H-13), 1.28 (3H, d, J=6.20 Hz, H-14), 1.63 (2H, m, H-12), 4.98 (1H, m, H-11), 6.22 (1H, d, J=13.41 Hz, H-8), 6.43 (1H, d, J=13.29 Hz, H-9), 6.68 (1H, dd, J=1.84, 7.88 Hz, H-4), 6.73 (1H, dd, J=1.00, 8.00 Hz, H-6), 7.18 (1H, t, J=8.04 Hz, H-5), 8.12 (1H, s, H-2), 8.52 (1H, s, 3-OH), 11.41 (1H, s, 1-NH).

EI-MS: m/z 263 {$[M]^+$, 25%}.

IR_{vmax} (neat) cm^{-1} : 3301.50 (N-H), 3160.70 (O-H), 2978.32 (C-H), 1692.05, 1650.82 (C=O).

DISCUSSION

The results show that the synthesized antibiotics had remarkable activity in the range 0.625 - 2.5µg/mL against the microorganisms for which they were active against. The derivatives showed higher activity than the analogue. This could be due to the reduction in polarity when the highly polar carboxylic functional group was converted to the less polar ester functional group [13 - 15]. This has been shown to increase cell membrane permeability. All the synthesized compounds showed better activity than the standard drugs used for comparison. The antibacterial standard drug, sparfloxacin, was up to four-fold less active than most of the synthesized derivatives while the antifungal standard drug, fluconazole, was up to ten-fold less active than the synthesized analogue and derivatives for the microorganism against which they were active. IA/37/1/B, IA/38/1/B, IA/39/1/B and IA/41/1/B were able to inhibit the growth of *C. ulcerans* whereas the standard antibacterial could not. All the derivatives and the standard antifungal could not inhibit the growth of *A. nigre*, but the analogue, (IA/09/1) was able to inhibit its growth. A few of the synthesized compounds could also not inhibit the growth of *S. pyogenes*. All the synthesized compounds could not inhibit the growths of *P. aeruginosa* and *T. rubrum*.

CONCLUSION

The results have shown that the synthesized compounds have a clear advantage over the tested standard drugs, and this has opened up the possibility of their application in the treatment of various ailments for which the tested microorganism are responsible for. The possible applications of these compounds are endless and with further studies could compliment or even replace some of the antibiotic drugs currently in the market if they are found to be less toxic and better tolerated. Other applications for the new antibiotics are in the veterinary and agricultural fields where they could be useful in combatting some of the diseases that plague both animals and plants. Some *in vivo* work is being carried out to establish the activity of the synthesized compounds as anti-cancer, anti-HIV, antimalarial, antitrypanosomiasis, anti-tuberculosis etc.

ACKNOWLEDGMENT

IAB would like to appreciate the Prof. F. O. Shode of the University of KwaZulu-Natal for providing laboratory space and PTDF, Nigeria for PhD local scholarship and the ETF, Nigeria for sponsoring part of this project.

REFERENCES

1. S. M. Aronson (1997), The naming of antibiotics, *Medical Health*, **80** (6), 180.

2. M. Radetsky (1996), The discovery of penicillin, *Pediatriatic Infectious Diseases Journal*, **15** (9), 811-818.

3. S. A. Waksman (1947), What Is an Antibiotic or an Antibiotic Substance? *Mycologia* **39** (5): 565-569.

4. F. vonNussbaum, M. Brands, B. Hinzen, S. Weigand, and D. Häbich (2006), Medicinal Chemistry of Antibacterial Natural Products - Exodus or Revival? *Angewandte Chemie International Edition*, **45** (31), 5072-5129.

5. H. B. Maruyama, Y. Suhara, J. Suzuki-Watanabe, Y. Maeshima, N. Shimizu, M. Ogura-Hamada, H. Fujimoto, and K. Takano (1975), A New Antibiotic, Fumaramidmycin: I. Production, Biological Properties and Characterization of Producer Strain, *Journal of Antibiotics*, **28**, 637-647.

6. T. Hasegawa, M. Asai, K. Haibara, T. Yamano, H. Iwasaki, and M. Yoneda (1975), A New Antibiotic, C-9154, *Journal of Antibiotics*, **28**, 713-717.

7. Y. Suhara, H. B. Maruyama, Y. Kotoh, Y. Miyasaka, K. Yokose, H. Shirai, and K. Takano (1975), A New Antibiotic, Fumaramidmycin: II. Isolation, Structure, and Synthesis. *Journal of Antibiotics*, **28**, 648-655.

8. J. Jumina, D. Siswanta, and A. K. Zulkarnain (2001), Sintesis dan Uji Aktivitas Biologis Turunan Antibiotik C-9154 Dari Vanilin. *Majalah Farmasi Indonesia.* **12** (3), 24-35.

9. J. Jumina, I. Tahir, and A. K. Zulkarnain (2002), Synthesis and Antimicrobe Activity Evaluation of Ethyl Salicyl Fumarate and Ethyl Furfuryl Fumarate. *Majalah Farmasi Indonesia*. **13** (4), 207-214.

10. J. Jumina, A. K. Zulkarnain, and P. Mulyono (2005), Preparation and antibacterial activity of p-Anisyl ethyl fumarate and ethyl N-phenyl fumaramate, *Majalah Farmasi Indonesia*, **16** (2), 116-123.

11. I. A. Bello, G. I. Ndukwe, J. O. Amupitan, R. G. Ayo, and F. O. Shode (2012), Syntheses and Biological Activity of Some Derivatives of C-9154 Antibiotic, *International Journal of Medicinal Chemistry*, 148235, 7 pages doi:10.1155/2012/148235

12. I. A. Bello, G. I. Ndukwe, J. O. Amupitan, R. G. Ayo, and F. O. Shode (2012), Syntheses and *In Vitro* Biological Activity of Some Derivatives of C-9154 Antibiotic. *International Journal of Medicinal Chemistry*, 782058, 6 pages doi:10.1155/2012/782058

13. F. L. Strand (1983), The plasma membrane as a regulatory organelle. In: *Physiology: A regulatory systems approach* (Second edition). MacMillan, New York, PP. 49-67.

14. Eckert, R., Randall, D. and Augustine, G. (1988), Permeability and transport. In: *Animal physiology* (Third edition). W. H. Freeman, New York, PP 65-99.

15. Alberts, B., Bray, D., Lewis, J., Raff, M., Roberts, K. and Watson, J. D. (1989), The Plasma membrane. In: *Molecular biology of the cell* (Second edition). Garland Publishing, New York, PP. 276-337.